PF-03550096
PF-03550096 is a drug that acts as a potent agonist for the CB2 cannabinoid receptor, with good selectivity over CB1 having Ki values of 7nM at CB2 and 1500nM at CB1. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,[1] but has only progressed to animal studies.[2]
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C19H28N4O4 |
| Molar mass | 376.457 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
See also
References
- WO 2008032164, Ando K, et al, "Benzimidazolone Derivatives", published 20 March 2008, assigned to Pfizer Products Inc.
- Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H (February 2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of Pharmacological Sciences. 106 (2): 219–24. doi:10.1254/jphs.FP0071599. PMID 18270474.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.